Overview
Platinum-resistant ovarian cancer (PROC), cancer that returns within 6 months of platinum chemotherapy, carries a poor prognosis and limited treatment options. While clinical guidelines recommend non-platinum chemotherapy for PROC, many patients still receive platinum re-challenge in real-world practice despite limited evidence of benefit. This study examined whether platinum rechallenge actually improves outcomes compared to non-platinum therapy.
Researchers used Flatiron Health’s US Ovarian Cancer Panoramic Database, inclusive of more than 30,000 patients with ovarian cancer, to analyze data from nearly 2,900 patients with PROC who received subsequent treatment between 2017-2025. Among them, 528 received platinum re-challenge and 2,379 received non-platinum therapy (mostly chemotherapy with or without bevacizumab). Platinum rechallenge was associated with significantly longer progression-free survival (5.8 months versus 3.9 months) and overall survival (13 months versus 11 months). These benefits were consistent across most patient subgroups, including those with and without BRCA mutations and those with varying degrees of prior treatment.
Why this matters
This large real-world study provides evidence that platinum re-challenge may benefit selected patients with platinum-resistant ovarian cancer. The findings suggest platinum-resistant disease is heterogeneous, with some patients (particularly those with BRCA mutations) potentially deriving greater benefit from rechallenge. These results support individualized treatment decisions beyond the standard 6-month platinum-free interval and highlight the need for prospective studies to identify which patients will benefit most from platinum rechallenge.